230 related articles for article (PubMed ID: 15322944)
21. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.
Clements PJ; Roth MD; Elashoff R; Tashkin DP; Goldin J; Silver RM; Sterz M; Seibold JR; Schraufnagel D; Simms RW; Bolster M; Wise RA; Steen V; Mayes MD; Connelly K; Metersky M; Furst DE;
Ann Rheum Dis; 2007 Dec; 66(12):1641-7. PubMed ID: 17485423
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
[TBL] [Abstract][Full Text] [Related]
23. [Scleroderma and its visceral complications].
Huriez C
Maroc Med; 1972 Jun; 52(558):331-44. PubMed ID: 4636029
[No Abstract] [Full Text] [Related]
24. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
[TBL] [Abstract][Full Text] [Related]
25. Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology.
Bhansing KJ; Lammens M; Knaapen HK; van Riel PL; van Engelen BG; Vonk MC
Arthritis Res Ther; 2014 May; 16(3):R111. PubMed ID: 24886750
[TBL] [Abstract][Full Text] [Related]
26. Nailfold capillaroscopy abnormalities correlate with cutaneous and visceral involvement in systemic sclerosis patients.
Sato LT; Kayser C; Andrade LE
Acta Reumatol Port; 2009; 34(2A):219-27. PubMed ID: 19474777
[TBL] [Abstract][Full Text] [Related]
27. Perifollicular Hypopigmentation in Systemic Sclerosis: Associations With Clinical Features and Internal Organ Involvement.
Chung MP; Mecoli CA; Perin J; Richardson C; McMahan ZH
J Rheumatol; 2022 May; 49(5):475-481. PubMed ID: 35169054
[TBL] [Abstract][Full Text] [Related]
28. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register.
Hanitsch LG; Burmester GR; Witt C; Hunzelmann N; Genth E; Krieg T; Lehmacher W; Melchers I; Meurer M; Müller-Ladner U; Schulze-Lohoff E; Becker M; Sunderkoetter C; ; Riemekasten G
Rheumatology (Oxford); 2009 Jan; 48(1):70-3. PubMed ID: 19056798
[TBL] [Abstract][Full Text] [Related]
29. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease.
Scalapino K; Arkachaisri T; Lucas M; Fertig N; Helfrich DJ; Londino AV; Steen VD; Medsger TA
J Rheumatol; 2006 May; 33(5):1004-13. PubMed ID: 16583463
[TBL] [Abstract][Full Text] [Related]
30. Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis.
Nishijima C; Sato S; Takehara K
J Rheumatol; 2001 Aug; 28(8):1847-51. PubMed ID: 11508588
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.
Elhai M; Meunier M; Matucci-Cerinic M; Maurer B; Riemekasten G; Leturcq T; Pellerito R; Von Mühlen CA; Vacca A; Airo P; Bartoli F; Fiori G; Bokarewa M; Riccieri V; Becker M; Avouac J; Müller-Ladner U; Distler O; Allanore Y;
Ann Rheum Dis; 2013 Jul; 72(7):1217-20. PubMed ID: 23253926
[TBL] [Abstract][Full Text] [Related]
32. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development.
Lambrecht S; Smith V; De Wilde K; Coudenys J; Decuman S; Deforce D; De Keyser F; Elewaut D
Arthritis Rheumatol; 2014 Feb; 66(2):418-27. PubMed ID: 24504814
[TBL] [Abstract][Full Text] [Related]
33. Associations of right ventricular myocardial function with skin and pulmonary involvement in asymptomatic patients with systemic sclerosis.
D'Andrea A; Bellissimo S; Scotto di Uccio F; Vigorito F; Moscato F; Tozzi N; Di Donato M; Citro R; Stisi S; Scherillo M
Ital Heart J; 2004 Nov; 5(11):831-9. PubMed ID: 15633438
[TBL] [Abstract][Full Text] [Related]
34. Outcome of patients with scleroderma admitted to intensive care unit. A report of nine cases.
Shalev T; Haviv Y; Segal E; Ehrenfeld M; Pauzner R; Levy Y; Langevitz P; Shoenfeld Y
Clin Exp Rheumatol; 2006; 24(4):380-6. PubMed ID: 16956427
[TBL] [Abstract][Full Text] [Related]
35. Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort.
Jung M; Bonner A; Hudson M; Baron M; Pope JE;
Scand J Rheumatol; 2014; 43(3):217-20. PubMed ID: 24650305
[TBL] [Abstract][Full Text] [Related]
36. Sparing effect of hemiplegia on skin fibrosis and microvascular involvement: reports of two cases of systemic sclerosis and review of the literature.
Ughi N; Hervey SA; Gualtierotti R; Silvana Z; Herrick AL; Ingegnoli F; Meroni P
Semin Arthritis Rheum; 2015 Apr; 44(5):597-601. PubMed ID: 25488380
[TBL] [Abstract][Full Text] [Related]
37. Clinical and laboratory features of systemic sclerosis complicated with localized scleroderma.
Toki S; Motegi S; Yamada K; Uchiyama A; Kanai S; Yamanaka M; Ishikawa O
J Dermatol; 2015 Mar; 42(3):283-7. PubMed ID: 25582037
[TBL] [Abstract][Full Text] [Related]
38. Anti-PM-Scl antibody in patients with systemic sclerosis.
Koschik RW; Fertig N; Lucas MR; Domsic RT; Medsger TA
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S12-6. PubMed ID: 22261302
[TBL] [Abstract][Full Text] [Related]
39. Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study.
Jaeger VK; Wirz EG; Allanore Y; Rossbach P; Riemekasten G; Hachulla E; Distler O; Airò P; Carreira PE; Balbir Gurman A; Tikly M; Vettori S; Damjanov N; Müller-Ladner U; Distler JH; Li M; Walker UA;
PLoS One; 2016; 11(10):e0163894. PubMed ID: 27706206
[TBL] [Abstract][Full Text] [Related]
40. Determinants of morbidity and mortality of systemic sclerosis in Canada.
Al-Dhaher FF; Pope JE; Ouimet JM
Semin Arthritis Rheum; 2010 Feb; 39(4):269-77. PubMed ID: 18706680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
